Holzgrefe H H, Everitt J M, Wright E M
Cardiovascular Diseases Research Laboratory, Upjohn Company, Kalamazoo, MI.
Lab Anim Sci. 1987 Oct;37(5):587-95.
Since its initial description in 1893, alpha-chloralose has undergone extensive pharmacologic evaluation. It has been characterized as a compound possessing potent CNS activity and has been evaluated in humans and animal models for its therapeutic properties. Though the toxicity of the compound prohibits its use as a human therapeutic agent, it has been employed widely as an animal anesthetic in the laboratory setting. A thorough search of the literature reveals that alpha-chloralose is second only to sodium pentobarbital as the primary anesthetic agent in acute cardiovascular studies where the preservation of myocardial function is a primary consideration. The literature also shows that alpha-chloralose is the subject of much controversy. The question as to whether alpha-chloralose is a true anesthetic or an immobilizing agent with sedative-hypnotic properties has important implications in light of the current emphasis on ethics in animal research.
自1893年首次被描述以来，α-氯醛糖已接受了广泛的药理学评估。它被认定为一种具有强大中枢神经系统活性的化合物，并已在人类和动物模型中对其治疗特性进行了评估。尽管该化合物的毒性使其无法用作人类治疗药物，但它在实验室环境中已被广泛用作动物麻醉剂。对文献的全面检索表明，在急性心血管研究中，α-氯醛糖作为主要麻醉剂仅次于戊巴比妥钠，在这类研究中，心肌功能的保存是首要考虑因素。文献还表明，α-氯醛糖存在诸多争议。鉴于当前动物研究中对伦理的重视，α-氯醛糖究竟是一种真正的麻醉剂还是一种具有镇静催眠特性的固定剂这一问题具有重要意义。
